Newly published scientific studies have ignited renewed hope for a dramatic breakthrough in stroke treatment for patients. An injectable compound that is currently in a Phase 1 human safety clinical… Read More
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations RAHWAY, N.J. — AstraZeneca and… Read More
LONDON, UK — GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge (Boston, Massachusetts). Affinivax has pioneered… Read More
First new treatment regimen in more than 20 years to significantly improve outcomes in people with this fast-growing type of lymphoma Application is based on pivotal data from the phase… Read More
BioTalent Canada has launched its first 45 National Occupational Standards (NOS) for Canada’s bio-economy. These standards were validated by industry stakeholders and will replace BioTalent Canada’s Skills Profiles and Skills At-A-Glances…. Read More
